Key facts
- This page summarizes Kelly A. Romano's Form 4 filing for Athira Pharma, Inc. (ATHA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jun 2024, 19:21.
Kelly A. Romano - 21 Jun 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)
- Reporting relationship
- Director
- Issuer ticker
- ATHA
- Reported as of
- 21 Jun 2024
- Net transaction value
- +$100,051
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2024, 19:21:55 UTC
- Prior SEC filing
- 04 Jun 2024
- Next SEC filing
- 04 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Worthington, Attorney in fact for Kelly A. Romano
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kelly A. Romano filed Form 4 for Athira Pharma, Inc. (ATHA) on 25 Jun 2024.
Change
- Previous filing in this sequence was filed on 04 Jun 2024.
- Current net transaction value: +$100,051.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATHA
transaction
Common Stock
Purchase
- Transaction value
- $33,872
- Shares
- +15,000
- Change %
- +39%
- Price
- $2.26
- Shares after
- 53,315
- Date
- 21 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
ATHA
transaction
Common Stock
Purchase
- Transaction value
- $66,179
- Shares
- +27,400
- Change %
- +51%
- Price
- $2.42
- Shares after
- 80,715
- Date
- 24 Jun 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.20 to $2.32, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Footnote F2
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.39 to $2.43, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.